Furthermore, our findings may benefit studies across a broad range of oncological indications due to the evidence that TFRC has been identified as a candidate therapeutic target because of its elevated expression in several types of cancer: brain, liver, breast, colon, ovarian, prostate, leukemia, and lung, with a push towards developing anti-TFRC antibodies to facilitate the delivery of anti-cancer drug conjugates, or for the disruption of TFRC function and, thereby, cancer progression [55,56]. Here, TFRC is linked to leukemia.